Ackman hires Credit Suisse in Allergan pursuit; Actavis wraps Furiex buyout;

@FiercePharma: Once again, top-read on FP yesterday: Sex, bribes and videotape: Clandestine video of $GSK exec adds to China scandal. Article | Follow @FiercePharma

@TracyStaton: ICYMI: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: ICYMI: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. More | Follow @EricPFierce

@CarlyHFierce: In case anybody missed this one, here are the top 5 vaccines by 2020. Feature | Follow @CarlyHFierce

> Activist investor Bill Ackman's Pershing Square Capital Management has hired Credit Suisse to advise it in its quest to help Valeant ($VRX) take over Allergan ($AGN). Report

> Actavis ($ACT) has completed its acquisition of Furiex Pharmaceuticals. Release

> Pfizer ($PFE) has appointed the Thomson Reuters CEO James Smith to its board of directors. Report

> AstraZeneca ($AZN) has filed a lawsuit against Mylan ($MYL) in the U.S. to block a generic version of diabetes drug Onglyza. More

> Salix Pharmaceuticals' ($SLXP) lead drug, Xifaxan, succeeded in a late-stage study of irritable bowel syndrome. Report

> Philip Johnson, head of IP at Johnson & Johnson ($JNJ), will become the next head of the U.S. Patent and Trademark Office. Story

> ANI Pharmaceuticals has acquired Lithobid Extended Release tablets from Noven Therapeutics. Release

Medical Device News

@FierceMedDev: Muscle cell-powered 'bio-bot' could carry drugs. Story | Follow @FierceMedDev

@StacyALawrence: In obesity device race, ReShape lines up with FDA. Article | Follow @StacyALawrence

@VarunSaxena2: AHRQ report highlights government concern over chronic wound care, home healthcare. Story | Follow @VarunSaxena2

@MichaelGFierce: Nanoparticles designed to prevent cancer, aid bones. More from Laboratory Equipment | Follow @MichaelGFierce

@EmilyWFierce: Which med tech CEOs took home the biggest paychecks in 2013? Find out here: Feature | Follow @EmilyWFierce

> Intuitive Surgical kicks off da Vinci sales in Japan. Article

> Med techs Cerus, Amedica score $56M in debt. Story

> Canada to implement UDI based solely on international guidelines. Report

Biotech News

@FierceBiotech: | Follow @FierceBiotech

@JohnCFierce: Interesting Porges note spotlights $GILD's 67% success rate in deals--95% success rate by $$$--since 2000. No doubt Sovaldi helped... | Follow @JohnCFierce

@DamianFierce: Oct. 2013: Seragon raises $30M Series A. July 2014: $RHHBY buys it for up to $1.7B. News | Follow @DamianFierce

@EmilyMFierce: Chikungunya: Tracing a Virus's Past to Predict its Future. Story from The Scientist | Follow @EmilyMFierce

> Nicox adds to eye-drug pipeline with $120M buyout deal for Aciex. Story

> Takeda's chief-in-waiting sees big M&A in the drugmaker's future. More

> IPO hopefuls swing for $126.5M and hope biotech's window stays open. Article

> Neuropsychiatric biotech raises $20M for PhII program. Item

> Jazz gambles up to $250M on a long-delayed rare-disease drug. News

Drug Delivery News

> Muscle cell-powered 'bio-bot' could carry drugs. Story

> Researchers aim to sneak antibiotics into bacteria via naturally occurring molecule. Article

> BMS recalls injectable warfarin, oral formulation unaffected. More

> MicroRNA delivery specialist Microlin Bio nears $30 million IPO. Article

> Targeted nanoparticles home in on myeloma and strengthen bones. Story

Diagnostics News

> Roche and New Zealand university launch lab team for Dx development and training. Article

> GE Healthcare's Alzheimer's imaging agent gains backing of key EU agency committee. News

> Report: Abbott is cutting diagnostics division jobs. More

> NIH keeps Corgenix Ebola Dx project running with new funding. Article

> Abcodia will license access to serum biobank for cardiovascular disease biomarker work. Story

Pharma Marketing News

> Facing threats from Purdue, Teva and Pfizer, Zogenix puts Zohydro follow-up into high gear. More

> The FDA should step up its own social-media action, NEJM researchers say. Report

> Study: Med students cozy with industry reps more likely to dole out branded drugs. More

> With a new IPF drug on its way, Boehringer backs a Discovery documentary on the lung disease. Story

> Now that it's FDA-approved, MannKind has to actually sell its inhaled insulin Afrezza. Article

> J&J, Pfizer in tug-of-war over ads for Infants' Advil. News

And Finally... The U.S. Men's National Soccer Team is tracking its movements to prevent injuries. More

Suggested Articles

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.